Subtractive genomics and molecular docking approach to identify drug targets against *Stenotrophomonas maltophilia*

Hira Saleem‡, Usman Ali Ashfaq‡, Habibullah Nadeem, Muhammad Zubair, Muhammad Hussnain Siddique, Ijaz Rasul*.

Department of Bioinformatics and Biotechnology, Government College University Faisalabad, Faisalabad, Pakistan

‡ HS and UAA are contributed equally to this work as first co-authors.

Abstract

*Stenotrophomonas maltophilia* is a multidrug resistant pathogen associated with high mortality and morbidity in patients having compromised immunity. The efflux systems of *S. maltophilia* include SmeABC and SmeDEF proteins, which assist in acquisition of multiple-drug-resistance. In this study, proteome based mapping was utilized to find out the potential drug targets for *S. maltophilia* strain k279a. Various tools of computational biology were applied to remove the human-specific homologous and pathogen-specific paralogous sequences from the bacterial proteome. The CD-HIT analysis selected 4315 proteins from total proteome count of 4365 proteins. Geptop identified 407 essential proteins, while the BlastP revealed approximately 85 non-homologous proteins in the human genome. Moreover, metabolic pathway and subcellular location analysis were performed for essential bacterial genes, to describe their role in various cellular processes. Only two essential proteins (Acyl-[acyl-carrier-protein]—UDP-N acetyl glucosamine O-acyltransferase and D-alanine-D-alanine ligase) as candidate for potent targets were found in proteome of the pathogen, in order to design new drugs. An online tool, Swiss model was employed to model the 3D structures of both target proteins. A library of 5000 phytochemicals was docked against those proteins through the molecular operating environment (MOE). That resulted in to eight inhibitors for both proteins i.e. enterodiol, aloin, ononin and rhinacanthinF for the Acyl-[acyl-carrier-protein]—UDP-N acetyl glucosamine O-acyltransferase and D-alanine-D-alanine ligase as candidate for potent targets were found in proteome of the pathogen, in order to design new drugs. An online tool, Swiss model was employed to model the 3D structures of both target proteins. A library of 5000 phytochemicals was docked against those proteins through the molecular operating environment (MOE). That resulted in to eight inhibitors for both proteins i.e. enterodiol, aloin, ononin and rhinacanthinF for the Acyl-[acyl-carrier-protein]—UDP-N acetyl glucosamine O-acyltransferase and rhazin, alkannin beta, aloesin and ancistrocadline for the D-alanine-D-alanine ligase. Finally the ADMET was done through ADMETsar. This study supported the development of natural as well as cost-effective drugs against *S. maltophilia*. These inhibitors displayed the effective binding interactions and safe drug profiles. However, further in vivo and in vitro validation experiment might be performed to check their drug effectiveness, biocompatibility and their role as effective inhibitors.
Introduction

*Stenotrophomonas maltophilia* is an intensive emergent gram-negative bacterium of the human-ecological origin worldwide. That characteristically impart resistance to different classes of antibiotics and hefty metals [1, 2]. It is responsible for wide scope infections in clinics and local area settings including infection of respiratory tract and septicemia which are pervasive in nature. Whereas infections of bone, joints, urinary tract as well as meningitis are less successive [3].

Owing to adaptive behavior of intrinsic resistance of *S. maltophilia* through horizontal gene transfer and mutation against anti-microbial utilized beforehand, the medicinal approach is getting popular nowadays [4]. The resistance emerges fundamentally by modifying the medication targets, bypassing molecules, efflux pumps, substance alteration, self-prescription, mutations or by phenotypic variation arising internally or externally by the host [5]. The efflux systems of *S. maltophilia* include SmeABC and SmeDEF proteins, which assist in acquisition of multiple-drug-resistance [4]. Furthermore, that offer an extreme tendency of fighting against drugs by extraordinary liability outcomes such as trimethoprim/sulfamethoxazole (TMP/SMX), fluoroquinolones and ceftazidime [6, 7]. Consequently it is of imperative significance to identify novel and potent therapeutic targets in *S. maltophilia* to cope with this multi-drug-resistant pathogen successfully.

The enormous progress in computational biology and diversified applications of bioinformatics have gained importance in drug designing thereby reducing the cost and time needed for in vivo screening and testing [8, 9]. The bioinformatics has substantially shortened traditional lab trials through employment of approaches including identification of drug candidates, structure-based designing of drug molecule, screening of antiviral drugs, comparative investigations utilizing genome to recognize host specific targets etc. [10, 11]. Currently the subtractive genomic approach is being focused in order to examine the entire host and proteome of bacterium. This is to recognize the proteins with various therapeutic perspectives solely present in the pathogenic genome, by excluding the homologous proteins of the host [12]. Numerous investigations have already utilized this approach on the multiple pathogenic strains and detailed fruitful identification and acknowledgment of novel species-specific therapeutic targets [13, 14].

The current study involves applying subtractive proteomics approach on the whole proteome of *S. maltophilia* (strain k279a) screen immunogenic proteins that may serve as novel drug targets. The overall flowchart of the study is shown (Fig 1).

Methods

The subtractive genomic approach was employed for analysis of the whole proteome of *S. maltophilia* (strain k279a) screen immunogenic proteins that may serve as novel drug targets. The overall flowchart of the study is shown (Fig 1).
The whole proteome retrieval
First of all the whole proteome of *S. maltophilia* (strain k279a) was retrieved from Uniprot in the FASTA format.

Identification of paralogous sequences
The whole proteome of *S. maltophilia* (strain k279a) was subjected to CD-HIT suite. The parameters were set to default except for threshold value kept to 60%. CD-HIT suite is widely employed for comparing and clustering protein and genomic sequences. That is to remove paralogs or redundant proteins [15].

Identification of essential proteins
The Geptop 2.0 server was used to retrieve essential proteins of *S. maltophilia*. That server is used for the detection of essential genes taking into account comparison of the phylogeny and orthology of provided query protein with datasets of essential genes.

Identification of essential non-homologous proteins
The essential proteins were submitted to Blastp against host proteome with a threshold of e-value $10^{-4}$, with the query coverage and identity of more than 70% and 30%, respectively. The purpose was to identify those proteins which are non-homologous to the host.

Analysis of metabolic pathways
The essential proteins of *S. maltophilia* were analyzed through KEGG automatic annotation server. The pathways unique to *S. maltophilia* (strain k279a) and absent in humans were selected [19] at KEGG [20].

---

Fig 1. Overall flow chart of subtractive genomic against *S. maltophilia*. This shows analysis of whole proteome of *S. maltophilia* (strain k279a).

https://doi.org/10.1371/journal.pone.0261111.g001
Subcellular localization analysis
The target proteins were subjected to the identification of subcellular localization of metabolic proteins of \textit{S. maltophilia} by the PSORTb tool to enable identification of these predicted therapeutic targets.

Selection of membrane proteins by drug-ability
In order to screen for the uniqueness of putative targets, Drug-Bank 5.1.0 database set to default limitations was used. Consequently, the proteins with significant hit higher to threshold with pre-treated drug targets displayed common functions. These were proceeded further for drug-able testing.

Primary and secondary structure analysis of target proteins
The evaluations of primary structure of selected proteins were done through EXPASY. It was followed by prediction of secondary structure through PSIPRED. That generated outcome based on feed-forward neural networks [16].

Furthermore, SignalP-5.0 server was used for the prediction of location for signal peptide and their protein cleavage sites. Subsequently these targets were tested for transmembrane topology via TMHMM tool. Which relies on Hidden Markov model for the prediction and so on predicts transmembrane helices and precisely distinguishes soluble from membrane proteins [17].

Structure prediction and validation
An online tool, Swiss-Model was employed to predict the 3D structure of putative proteins. That tool identifies the template, aligns it with the target sequence, constructs and evaluates quality of the 3D model [18]. The Chimera Structure Visualization software [19] was used to visualize and Galaxy WEB server was used to refine the models. The quality of model was evaluated using SAVES server which analyzes them on the basis of ERRAT [20], WHATCHECK [21] and PROCHECK [22].

Compounds library preparation and molecular docking
For docking, the 2D conformation of compounds were downloaded from the PubChem [23] followed by protonation and energy minimization in MOE software and further added to the database. These compounds were then docked with putative proteins via the MOE software [24].

Physiochemical property profiling and toxicity predictions
Molinspiration server was used to analyze the molecular descriptors and drug likeliness properties of compounds. In fact that gives a prediction based ‘rule of five’ (Ro5) [25]. AdmetSAR database was used to indicate the pharmacokinetic properties such as ADMET toxicity of the compounds [26]. ProTox-II webserver used for selected molecules were subjected to various toxicity screening endpoints models. That is a web server designed to predict the toxicity of various toxicological endpoints for different chemical compounds [27].

Results
This study was done to recognize the novel drug targets in \textit{S. maltophilia}. In this study, the subtractive genomic approach is employed for seeking therapeutic target proteins which are
indispensable for the bacterial survival but absent in the host. The insight of that approach is shown (Fig 2).

**Selection of paralogous sequences**

The proteome of *S. maltophilia* strain was based on 4365 proteins which were subsequently subjected to the CD-HIT server that facilitated selection of paralogous sequences. It was followed by excluding paralogous sequences showing similarity more than 60% thereby retaining back to 4315 non paralogous proteins.

**Selection of essential proteins**

The screening of 4315 non-paralogous proteins using Geptop 2.0 server resulted in 407 essential proteins. Actually designing of antibacterial compounds relies on docking and hinders with essential proteins [28].

**Selection of non-homologous proteins**

The cellular proteins of humans evolved to be homologous with bacteria [29] that necessitate the therapeutics to be non-homologous to humans to avoid cross-reactivity. Out of 407 proteins subjected to BlastP, 85 revealed as non-homologous.

**Metabolic pathway analysis**

The analysis of those 85 non homologous proteins appeared to be involved in 33 pathways explored with KEGG. Among these 33 pathways, 13 were predicted to be particular for the *S. maltophilia* and remaining to be common for the *S. maltophilia* as well as host. Briefly, 27 essential proteins are revealed to participate in 13 pathways (Table 1). Among these 27 proteins
Table 1. Essential non-homologous proteins involved in 27 unique metabolic pathways.

| SrNo. | Protein Name (ID)                                 | Unique Pathway                                      | Common pathway                                                                 |
|-------|--------------------------------------------------|----------------------------------------------------|--------------------------------------------------------------------------------|
| 1     | Bifunctional protein (B2FHY5)                    | Sm100541-O-Antigen nucleotide sugar biosynthesis   | Sm100520-Amino sugar and nucleotide sugar metabolism                          |
|       |                                                  | Sm101100-Metabolic pathways                        |                                                                                |
| 2     | Ubiquinone/menaquinone biosynthesis C-methyl transferase (B2FUU6) | Sm101110-Biosynthesis of secondary metabolites     | Sm101240 -Biosynthesis of cofactors                                            |
|       |                                                  | Sm100130-Ubiquinone and other terpenoid-quinone biosynthesis | Sm101100-Metabolic pathways                                                  |
| 3     | UDP-N-acetyl glucosamine 1-carboxyvinyltransferase (B2FRX1) | Sm100550- Peptidoglycan biosynthesis               | Sm101100-Metabolic pathways                                                  |
| 4     | D-alanine—D-alanine ligase (B2FNN9)               | Sm101502-Vancomycin resistance                     |                                                                                |
|       |                                                  | Sm100550- Peptidoglycan biosynthesis               |                                                                                |
|       |                                                  | Sm100473-D-Alanine metabolism                      |                                                                                |
| 5     | Phosphatidate cytidylyltransferase (B2FIA3)       | Sm101110-Biosynthesis of secondary metabolites     | Sm101100-Metabolic pathways                                                  |
|       |                                                  | Sm100564-Glycerophospholipid metabolism            |                                                                                |
| 6     | B2FNL3                                           | Sm101110-Biosynthesis of secondary metabolites     | Sm101100-Metabolic pathways                                                  |
|       |                                                  | Sm101240- Biosynthesis of cofactors                |                                                                                |
|       |                                                  | Sm100740- Riboflavin metabolism                    |                                                                                |
| 7     | UDP-N-acetyluramate—L-alanine ligase (B2FNN8)     | Sm100550- Peptidoglycan biosynthesis               | Sm100471-D-Glutamine and D-glutamate metabolism                               |
|       |                                                  | Sm101100-Metabolic pathways                        |                                                                                |
| 8     | UDP-2,3-diacylglycerol hydrolase (B2FQP4)         | Sm100540- Lipopolysaccharide biosynthesis          | Sm101100-Metabolic pathways                                                  |
| 9     | Acyl-[acyl-carrier-protein]—UDP-N acetyl glucosamine O-acyltransferase (B2FHN6) | Sm101503-Cationic antimicrobial peptide (CAMP) resistance. | Sm101100-Metabolic pathways                                                  |
|       |                                                  | Sm100540- Lipopolysaccharide biosynthesis          |                                                                                |
| 10    | 2-Dehydro-3-deoxyphosphoocotenate aldolase (B2FK85) | Sm100540- Lipopolysaccharide biosynthesis          | Sm101100-Metabolic pathways                                                  |
| 11    | Histidine biosynthesis bifunctional protein (B2FPM1) | Sm101110-Biosynthesis of secondary metabolites     | Sm101230- Biosynthesis of amino acids                                           |
|       |                                                  | Sm100340-Histidine metabolism                      |                                                                                |
| 12    | Shikimate kinase (B2FQ17)                        | Sm101110-Biosynthesis of secondary metabolites     | Sm101100-Metabolic pathways                                                  |
|       |                                                  | Sm101230- Biosynthesis of amino acids               |                                                                                |
|       |                                                  | Sm100400- Phenylalanine, tyrosine and tryptophan biosynthesis |                                                                                |
| 13    | Acetyl-coenzyme A carboxylase (B2FHN1)            | Sm101110-Biosynthesis of secondary metabolites     | Sm100061- Fatty acid biosynthesis                                              |
|       |                                                  | Sm101200- Microbial metabolism in diverse environments | Sm101100-Metabolic pathways                                                  |
|       |                                                  | Sm101200- Carbon metabolism                        |                                                                                |
|       |                                                  | Sm101212- Fatty acid metabolism                     |                                                                                |
|       |                                                  | Sm100640- Propanoate metabolism                     |                                                                                |
|       |                                                  | Sm100620- Pyruvate metabolism                       |                                                                                |
| 14    | Glutamyl-tRNA reductase (B2FQ15)                  | Sm101110-Biosynthesis of secondary metabolites     | Sm101100-Metabolic pathways                                                  |
|       |                                                  | Sm101120- Microbial metabolism in diverse environments | Sm101240- Biosynthesis of cofactors                                           |
|       |                                                  | Sm101100-Metabolic pathways                        |                                                                                |
|       |                                                  | Sm100860- Porphyrin and chlorophyll metabolism      |                                                                                |
| 15    | 3-Methyl-2-oxobutanoate hydroxymethyltransferase (B2FL53) | Sm101110-Biosynthesis of secondary metabolites     | Sm100770- Pantothenate and CoA biosynthesis                                    |
|       |                                                  | Sm101100-Metabolic pathways                        |                                                                                |
|       |                                                  | Sm101240- Biosynthesis of cofactors                 |                                                                                |
| 16    | 4-Hydroxy-3-methylbut-2-enyl diposphate reductase (B2FU83) | Sm101110-Biosynthesis of secondary metabolites     | Sm100900- Terpenoid backbone biosynthesis                                     |
|       |                                                  | Sm101100-Metabolic pathways                        |                                                                                |

(Continued)
which were analyzed in KEGG database, 24 proteins were found to participate in common metabolic pathways and rest of three namely chromosomal replication initiator protein DnaA, D-alanine-D-alanine ligase and Acyl-[acyl-carrier-protein]—UDP-N acetyl glucosamine O-acyltransferase were observed to participate in the pathogen specific pathways. Hence, continued further for analysis.

Subcellular localization prediction

The prediction of subcellular location is a quick way to obtain protein as it facilitates the steps required to purify in the experimental setup. That is done by determining its location i.e. whether cytoplasmic or membranous. The prediction retrieved via PSORTb revealed those proteins to be cytoplasmic in nature (Table 2).
Selection of drug-able proteins

Those 3 putative proteins were subjected to the Drug Bank. Two of them were found to be significantly similar to drug entries of the database, either to FDA approved or experimental drugs. These might act as potential novel drug targets (Table 3).

Structural analysis of target protein

The analysis of primary structure revealed that the D-alanine—D-alanine ligase protein and Acyl-[acyl-carrier-protein]—UDP-N acetyl glucosamine O-acyltransferase harbor the molecular mass of 21.07 kDa and 28.1 kDa, respectively. Moreover, their isoelectric points were 4.87 and 6.47, grand averages of hydrophobic (GRAVY) were 0.004 and -0.100, terminating amino acid at the N-terminus of protein was lysine and methionine and the instability indices were 30.98 and 18.93, respectively. As these proteins carried isoelectric points below 7 so that is an indication of positively charged proteins. Moreover, the GRAVY computed values explained them as hydrophilic and unstable.

Further, the secondary structure of Acyl-[acyl-carrier-protein]—UDP-N acetyl glucosamine O-acyltransferase and D-alanine-D-alanine ligase protein showed that they have 27.38% and 32.19% of alpha helices, 24.33% and 18.44% extended, and 48.29% and 49.38% of random coils, respectively. Both proteins displayed no beta turns.

The signal peptide probability values of Acyl-[acyl-carrier-protein]—UDP-N acetyl glucosamine O-acyltransferase and D-alanine-D-alanine ligase were obtained by SignalP. These values were 0.012 and 0.021, respectively. That was indicating the absence of signal peptide in these protein targets. The TMHMM showed absence of transmembrane helices in both putative proteins.

The 3D structure prediction and validation

The structures of both proteins Acyl-[acyl-carrier-protein]—UDP-N acetyl glucosamine O-acyltransferase and D-alanine-D-alanine ligase were predicted by the Swiss-Model with
confidence level of 100% and coverages were 92% and 98%, respectively. The SAVES analyzed those models by visualizing through Verify 3D, WHATCHECK, Prove, PROCHECK and ERRAT. The RAMPAGE server generated the Ramachandran plot for Acyl-[acyl-carrier-protein]—UDP-N acetyl glucosamine O-acyltransferase. This displayed that 96.9% of residues were found in the most favored regions, 0.3% of residues in additional allowed regions, 2.8% of residues in generously allowed region and none in disallowed region. According to the Ramachandran plot generated for D-alanine-D-alanine ligase, 85.8% of residues were found in the most favored region, while 13.7% and 13.2% of amino acids resided in additional allowed regions, and 0.8% and 1.0% of residues are found in generously allowed region and none in disallowed region (Figs 3 & 4).

Fig 3. Structure of the D-alanine-D-alanine ligase protein. (A) Three dimensional structure of D-alanine-D-alanine ligase protein. (B) Ramachandran Plot of D-alanine-D-alanine ligase protein.

https://doi.org/10.1371/journal.pone.0261111.g003

Fig 4. Structure of the Acyl-[acyl-carrier-protein]—UDP-N acetyl glucosamine O-acyltransferase protein. (A) Three dimensional structure of Acyl-[acyl-carrier-protein]—UDP-N acetyl glucosamine O-acyltransferase protein. (B) Ramachandran Plot of Acyl-[acyl-carrier-protein]—UDP-N acetyl glucosamine O-acyltransferase protein.

https://doi.org/10.1371/journal.pone.0261111.g004
Molecular docking
The minimum binding energy and scoring function of each docked ligand are shown (Table 4). The LigX interaction diagrams showed that Acyl-[acyl-carrier-protein]—UDP-N acetyl glucosamine O-acyltransferase (B2FHN6) interacts with the enterodiol, aloin, ononin and rhinacanthinF having binding scores -11.36, -17.44, -15.42 and -12.86, respectively. While D-alanine-D-alanine ligase (B2FNN9) interacted with ligands including rhazin, alkannin beta, aloesin and ancistrocladine having the docking scores -12.58, -12.57, -14.39 and -14.41, respectively. All these compounds exhibited RMSD below 3 which is an indication of the sound interaction. The 2D and 3D interaction diagrams are displayed (Figs 5 & 6).

ADMET/Drug scans results
The drug likeliness of compounds was predicted through the Molinspiration server, based on the Ro5. The selected candidates indicate zero violations to Lipinski’s Ro5 and showed acceptable drug-like properties (Table 5). All candidate compounds were assessed for the pharmacokinetic properties through the AdmetSAR server for drug likeliness (Table 6).

Table 4. The table displays the docking score and RMSD value for the compounds.

| PubChem ID | Compound Name                      | S-score | RMSD_Refine |
|------------|------------------------------------|---------|-------------|
| 115089     | Enterodiol                         | -11.36  | 3.0         |
| 14989      | Aloin                              | -17.44  | 1.7         |
| 442813     | Ononin                             | -15.42  | 2.5         |
| 10411189   | RhinacanthinF                      | -12.86  | 1.4         |
| 21160714   | Rhazin                             | -12.58  | 2.4         |
| 442720     | Alkannin beta, beta-dimethylacrylate | -12.57 | 1.4         |
| 160190     | Aloesin                            | -14.39  | 2.6         |

https://doi.org/10.1371/journal.pone.0261111.g005

Fig 5. 2D and 3D interaction diagram of Acyl-[acyl-carrier-protein]—UDP-N acetyl glucosamine O-acyltransferase protein. The structure shows complex with Enterodiol.

https://doi.org/10.1371/journal.pone.0261111.g006
Toxicity assessment

The rat oral acute toxicity (LD50) as mg/kg, toxicity classes (I–VI) predicted with accuracy in percent, the prediction of hepatotoxicity and cytotoxicity with their probability are indicated (Table 7).

Among these compounds, enterodiol, ononin and rhinacanthinF exhibited the highest toxicity. Those belong to the class V i.e. prescribed as harmful when swallowed (2000 < LD50 ≤ 5000) with accuracy of 69.26%, 64.71% and 68.7%, respectively. While ononin predicted to have class III (50 < LD50 ≤ 300) prescribed as toxic if swallowed with accuracy of 68.07%. Moreover, other compounds like alkannin beta, aloesin and ancistrocladine belonging to class IV i.e prescribed as harmful after swallowing (300 < LD50 ≤ 2000) with accuracy of 72.9%, 67.38% and 69.26%, respectively. While the compound Rhazin was predicted to have class III (50 < LD50 ≤ 300) prescribed as toxic if swallowed with accuracy of 68.07%. All these compounds were predicted to show hepatotoxicity and cytotoxicity inactive with probability values are shown (Figs 7 & 8).

![Fig 6](https://doi.org/10.1371/journal.pone.0261111.g006)

**Fig 6.** 2D and 3D interaction diagram of D-alanine-D-alanine ligase protein. The structure shows complex with Rhazin.

### Table 5. Results of inhibitors examined for Lipinski rule.

| PubChem ID | Compound Name                      | Molecular Weight | Number of HBA | Number of HBD | MlogP |
|-----------|-----------------------------------|------------------|---------------|---------------|-------|
| 115089    | Enterodiol                        | 302.37           | 4             | 4             | 2.10  |
| 14989     | Aloin                             | 418.40           | 7             | 3             | 0.89  |
| 442813    | Ononin                            | 430              | 9             | 4             | 0.65  |
| 10411189  | RhinacanthinF                     | 444.44           | 9             | 0             | 2.52  |
| 21160714  | Rhazin                            | 352.43           | 4             | 2             | 2.57  |
| 442720    | Alkannin beta, beta-dimethylacrylate | 370.40       | 6             | 2             | 3.67  |
| 160190    | Aloesin                           | 394.38           | 9             | 5             | -0.55 |
| 161741    | Ancistrocladine                   | 407.51           | 5             | 2             | 5.14  |

[https://doi.org/10.1371/journal.pone.0261111.t005](https://doi.org/10.1371/journal.pone.0261111.t005)
**Discussion**

*Stenotrophomonas maltophilia* (strain k279a) is a multidrug-resistant (MDR) bacterium. There is currently no effective vaccine for that but frequent and thorough hand washing can prevent person-to-person transmission [1]. Recent advances in the disciplines of bioinformatics as well as computational biology have created a variety of approaches to drug designing and *in silico* analysis, reducing the time and expenses associated with trial and error of ions devoted to drug development [30].

The whole proteome of *S. maltophilia* (strain k279a) contained 4365 proteins, was analyzed through CD-HIT that eliminated all the redundant proteins and provided a group of 4315 non-redundant proteins. For the survival of bacteria, essential genes are necessary [31]. Essential genes are preferred targets for vaccine development and antibacterial drugs [32]. Thus 407 essential genes were screened from non-redundant proteins. These genes could be homologous to human [33]. Thus, targeting such genes may interfere with human metabolism and might be fatal. The possibility of cross-reactivity as well as adverse events might be reduced by

| Compounds | Enterodiol | Aloin | Ononin | RhinacanthinF | Rhazin | Alkannin beta, beta-dimethylacrylate | Aloesin | Ancistrocladine |
|-----------|------------|-------|--------|---------------|--------|--------------------------------------|---------|----------------|
| Absorption | +          | -     | -      | -             | +      | -                                   | -       | -              |
| Blood Brain Barrier | +          | -     | -      | +             | +      | +                                   | +       | +              |
| Human Intestinal Absorption | +          | +     | -      | -             | +      | +                                   | +       | +              |
| Metabolism | P-glycoprotein substrate | -     | -      | -             | -      | -                                   | -       | -              |
| CYP1A2 Inhibitor | No         | No    | No     | Yes           | Yes    | Yes                                 | No      | No             |
| CYP 450 2C19 Inhibitor | No         | No    | No     | Yes           | No     | Yes                                 | No      | No             |
| CYP 450 2D9 Inhibitor | Yes        | No    | No     | Yes           | No     | Yes                                 | No      | Yes            |
| CYP 450 2C19 Inhibitor | Yes        | No    | No     | Yes           | No     | Yes                                 | No      | No             |
| CYP 450 3A4 Inhibitor | No         | No    | No     | Yes           | No     | Yes                                 | Yes     | Yes            |

| Subcellular Localization | Mitochondria | Mitochondria | Mitochondria | Mitochondria | Mitochondria | Mitochondria | Mitochondria |
|--------------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| Toxicity | AMES Toxicity | No | No | No | No | No | No | No |

https://doi.org/10.1371/journal.pone.0261111.1006

---

**Table 7. Prediction of class and accuracy, organ toxicity, oral acute toxicity and genetic toxicity endpoints of candidate compounds.**

| Sr. No | Compound name | Oral LD50 value (mg/Kg) | Predicted toxicity class | Prediction accuracy (%) | Hepatotoxicity | Probability | Cytotoxicity | Probability |
|--------|---------------|--------------------------|--------------------------|-------------------------|----------------|-------------|-------------|-------------|
| 1      | Enterodiol    | 2950                      | V                        | 69.26%                  | Inactive       | 0.80        | Inactive    | 0.93        |
| 2      | Aloin         | 221                       | III                      | 68.07%                  | Inactive       | 0.85        | Inactive    | 0.83        |
| 3      | Ononin        | 3100                      | V                        | 64.71%                  | Inactive       | 0.85        | Inactive    | 0.83        |
| 4      | RhinacanthinF | 4000                      | V                        | 68.07%                  | inactive       | 0.83        | Inactive    | 0.95        |
| 5      | Rhazin        | 300                       | III                      | 68.07%                  | Inactive       | 0.85        | Inactive    | 0.69        |
| 6      | Alkannin beta, beta-dimethylacrylate | 1000 | IV | 72.9% | Inactive | 0.54 | Inactive | 0.88 |
| 7      | Aloesin       | 832                       | IV                       | 67.38%                  | Inactive       | 0.80        | Inactive    | 0.78        |
| 8      | Ancistrocladine | 450                   | IV                       | 69.26%                  | inactive       | 0.64        | Inactive    | 0.51        |

https://doi.org/10.1371/journal.pone.0261111.1007
the selection of non-homologous proteins that are not found in *Homo sapiens* [34]. To avoid such undesirable circumstances and toxicity, we screened 85 non-homologous proteins. It might be the best strategy to target and develop inhibitors against non-homologous sequences for the production of new drugs [35].

**Fig 7.** Graphical representation of predicted dose value distribution for Acyl-[acyl-carrier-protein]—UDP-N acetyl glucosamine O-acyltransferase protein. In this graph, x-axis represents distribution of dose value and y-axis represents fraction of compounds.

https://doi.org/10.1371/journal.pone.0261111.g007

**Fig 8.** Graphical representation of predicted dose value distribution for D-alanine-D-alanine ligase. In this graph, x-axis represents distribution of dose value and y-axis represents fraction of compounds.

https://doi.org/10.1371/journal.pone.0261111.g008
Only two proteins Acyl-[acyl-carrier-protein]—UDP-N acetyl glucosamine O-acyltransferase and D-alanine-D-alanine ligase were involved in a unique metabolic pathway. Different tools were applied to determine the sequence and structural features as well as functions and localization of that protein. Both proteins were found to be cytoplasmic as predicted by PSORTb [36]. A proper identification of the potential drug targets and inhibitors is crucial for the treatment of this disease due to their emerging multidrug resistance (MDR) patterns. In this study, a systematic subtractive approach was implemented for the identification of novel therapeutic targets of S. maltophilia through genome-wide metabolic pathway analysis of the essential genes and proteins. ADMET analyses were also made for the identification of potential inhibitors as well. Then, we found unique proteins as novel targets. Therapeutic targets and its inhibitors might give some breakthrough to treat Stenotrophomonas maltophilia efficiently in in vitro [37].

An online tool, Swiss-model was employed to model the 3D structure of Acyl-[acyl-carrier-protein]—UDP-N acetyl glucosamine O-acyltransferase and D-alanine-D-alanine ligase proteins [38]. The prediction of 3D structures provided the great aid in studying protein functions, dynamics, ligand interactions and other protein components [39]. Analysis of the Ramachandran plot showed that most residues were present in the acceptable as well as favored areas and few residues in the disallowed regions [40]. The ERRAT quality factor and z-score proved that structures of the Acyl-[acyl-carrier-protein]—UDP-N acetyl glucosamine O-acyltransferase and D-alanine-D-alanine ligase protein were of good quality.

Molecular docking was performed to find out the compounds exhibiting the best residue interaction with the target protein [26]. Out of 5000 docked molecules, eight (8) top molecules for both proteins: enterodiol, aloin, ononin, rhinacanthinF, rhazin, alkannin beta, aloesin and ancistrocladin were selected based on low score i.e. rmsd < 3 and different interacting residues. Based on “Lipinski’s Rule of Five” molecular profile and drug probability of these eight compounds were assessed. Those compounds were then tested for penetration of the blood-brain barrier (BBB), Human intestinal absorption (HIA) as well as AMES monitoring. Predicting the ADMET properties is a significant indicator of the behavior, toxicity level and fate of the drug candidate in the human body [41]. It provides a likelihood of the candidate’s ability to enter the intestinal absorption, metabolism, blood-brain barrier, subcellular localization and most significantly the level of harm that it can cause to the body [42]. The superfamily cytochrome P450 consists of isoforms such as CYP2A6, CYP1A2, CYP2C9, CYP2D6, CYP2C19, CYP3A4 and CYP2E1 which are involved in drug metabolism as well as hepatic clearance. So, inhibiting the cytochrome P450 isoforms can result in drug-drug interaction that hinders the metabolism of concomitant drugs that cause its accumulation to toxic levels [43]. Admet SAR showed that drugs exhibit localization in mitochondria. The compound localized in mitochondria show no toxicity. The ADMET profile of those compounds indicated that they have no adverse effects on absorption [44].

Various toxicity modules were subjected to the eight compounds obtained after the virtual screening [42]. Toxicity evaluation results revealed that none of the compounds was found to be cytotoxic, hepatotoxic as well as mutagenic [43].

Conclusions
The subtractive genomics approach in our study has indicated two proteins of S. maltophilia as novel drug targets. The probability of cross reactivity seem to be ruled out between drugs and host proteins because there was no similarity between the proteome and 'anti-targets'. Thus development of the putative target against S. maltophilia might be significantly effective for the eradication of otherwise resulting disease.
Acknowledgments
We are thankful to Department of Bioinformatics and Biotechnology, Government College University, Faisalabad, Pakistan for providing computational facilities for successful completion of this project.

Author Contributions
Conceptualization: Usman Ali Ashfaq.
Data curation: Hira Saleem.
Formal analysis: Hira Saleem, Habibullah Nadeem.
Investigation: Muhammad Zubair.
Methodology: Hira Saleem, Muhammad Hussnain Siddique, Ijaz Rasul.
Project administration: Usman Ali Ashfaq, Ijaz Rasul.
Software: Muhammad Zubair, Muhammad Hussnain Siddique.
Supervision: Ijaz Rasul.
Validation: Habibullah Nadeem.
Writing – original draft: Hira Saleem, Ijaz Rasul.
Writing – review & editing: Usman Ali Ashfaq, Ijaz Rasul.

References
1. Brooke J.S., *Stenotrophomonas maltophilia*: an emerging global opportunistic pathogen. Clinical microbiology reviews, 2012. 25(1): p. 2–41. https://doi.org/10.1128/CMR.00019-11 PMID: 22232370
2. Looney W.J., Narita M., and Mühlemann K., *Stenotrophomonas maltophilia*: an emerging opportunistic human pathogen. The Lancet infectious diseases, 2009. 9(5): p. 312–323. https://doi.org/10.1016/S1473-3099(09)70083-0 PMID: 19393961
3. Nseir S., et al., Intensive care unit-acquired *Stenotrophomonas maltophilia*: incidence, risk factors, and outcome. Critical Care, 2006. 10(5): p. 1–9. https://doi.org/10.1186/cc5063 PMID: 17026755
4. Sánchez M.B., Antibiotic resistance in the opportunistic pathogen *Stenotrophomonas maltophilia*. Frontiers in microbiology, 2015. 6: p. 658. https://doi.org/10.3389/fmicb.2015.00658 PMID: 26175724
5. Wright G.D., Molecular mechanisms of antibiotic resistance. Chemical communications, 2011. 47(14): p. 4055–4061. https://doi.org/10.1039/c0cc05111j PMID: 21286630
6. Brooke J.S., New strategies against *Stenotrophomonas maltophilia*: a serious worldwide intrinsically drug-resistant opportunistic pathogen. Expert review of anti-infective therapy, 2014. 12(1): p. 1–4. https://doi.org/10.1586/14787210.2014.864553 PMID: 24308713
7. Chang Y.T., et al., Update on infections caused by *Stenotrophomonas maltophilia* with particular attention to resistance mechanisms and therapeutic options. Frontiers in microbiology, 2015. 6: p. 893. https://doi.org/10.3389/fmicb.2015.00893 PMID: 26388847
8. Barh D., et al., In silico subtractive genomics for target identification in human bacterial pathogens. Drug Development Research, 2011. 72(2): p. 162–177.
9. Lin X., Li X., and Lin X., A review on applications of computational methods in drug screening and design. Molecules, 2020. 25(6): p. 1375. https://doi.org/10.3390/molecules25061375 PMID: 32197324
10. Zhu H., Big data and artificial intelligence modeling for drug discovery. Annual review of pharmacology and toxicology, 2020. 60: p. 573–589. https://doi.org/10.1146/annurev-pharmtox-010919-023324 PMID: 31518513
11. Lakshmi P. and Ramyachitra D., Review About Bioinformatics, Databases, Sequence Alignment, Docking, and Drug Discovery, in Statistical Modelling and Machine Learning Principles for Bioinformatics Techniques, Tools, and Applications. 2020, Springer. p. 11–23.
12. Chakrabarty R.P., et al., Identification and qualitative characterization of new therapeutic targets in *Stenotrophomonas maltophilia* through in silico proteome exploration. Microbial pathogenesis, 2020. 149: p. 104293. https://doi.org/10.1016/j.micpath.2020.104293 PMID: 32531498

13. Hossain T., et al., Application of the subtractive genomics and molecular docking analysis for the identification of novel putative drug targets against Salmonella enterica subsp. enterica serovar Poona. BioMed research international, 2017. 2017. https://doi.org/10.1155/2017/3783714 PMID: 28904956

14. Mondal S.I., et al., Identification of potential drug targets by subtractive genome analysis of *Escherichia coli* O157: H7: an in silico approach. Advances and applications in bioinformatics and chemistry: AABC, 2015. 8: p. 49. https://doi.org/10.2147/AABC.S88522 PMID: 26677339

15. Huang Y., et al., CD-HIT Suite: a web server for clustering and comparing biological sequences. Bioinformatics, 2010. 26(5): p. 680–682. https://doi.org/10.1093/bioinformatics/btp003 PMID: 20053844

16. Birzele F. and Kramer S., A new representation for protein secondary structure prediction based on frequent patterns. Bioinformatics, 2006. 22(21): p. 2628–2634. https://doi.org/10.1093/bioinformatics/bt6453 PMID: 16940325

17. Krogh A., et al., Predicting transmembrane protein topology with a hidden Markov model: to complete genomes. Journal of molecular biology, 2001. 305(3): p. 567–580. https://doi.org/10.1006/jmbi.2000.4315 PMID: 11152613

18. Waterhouse A., et al., SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic acids research, 2018. https://doi.org/10.1093/nar/gky427 PMID: 29788355

19. Pettersen E.F., et al., UCSF Chimera—a visualization system for exploratory research and analysis. Journal of computational chemistry, 2004. 25(13): p. 1605–1612. https://doi.org/10.1002/jcc.20084 PMID: 15264254

20. Colovos C. and Yeates T.O., Verification of protein structures: patterns of nonbonded atomic interactions. Protein science, 1993. 2(9): p. 1511–1519. https://doi.org/10.1002/pro.5560020916 PMID: 8401235

21. Hoof R.W., et al., Errors in protein structures. Nature, 1996. 381(6580): p. 272. https://doi.org/10.1038/381272a0 PMID: 8692262

22. Laskowski R.A., et al., AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. Journal of biomolecular NMR, 1996. 8(4): p. 477–486. https://doi.org/10.1002/jmb.268 PMID: 9008363

23. Bolton E.E., et al., PubChem: integrated platform of small molecules and biological activities, in Annual reports in computational chemistry. 2008, Elsevier. p. 217–241.

24. Inc., C.C.G., Molecular operating environment (MOE). 2016, Chemical Computing Group Inc 1010 Sherbooke St. West, Suite# 910, Montreal, QC, Canada, H3A 2R7.

25. Lipinski C.A., et al., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings1. Advanced drug delivery reviews, 2001. 46(1–3): p. 3–26. https://doi.org/10.1016/s0169-409x (00)00129-0 PMID: 11259830

26. Yang H., et al., admetSAR 2.0: web-service for prediction and optimization of chemical ADMET properties. Bioinformatics, 2019. 35(6): p. 1067–1069. https://doi.org/10.1093/bioinformatics/bty707 PMID: 30165565

27. Banerjee P., et al., ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic acids research, 2018. 46(W1): p. W257–W263. https://doi.org/10.1093/nar/gky318 PMID: 29718510

28. Zhang R., Ou H.Y., and Zhang C.T., DEG: a database of essential genes. Nucleic acids research, 2018. https://doi.org/10.1093/nar/gky427 PMID: 29788355

29. Hediger M.A., Turk E., and Wright E.M., Homology of the human intestinal Na+/glucose and Na+/proline cotransporters. Proceedings of the National Academy of Sciences, 1989. 86(15): p. 5748–5752.

30. Asalone K.C., Nelson M.M., and Bracht J.R., Novel Sequence Discovery by Subtractive Genomics. J Vis Exp, 2019(143). https://doi.org/10.3791/58877 PMID: 30735163

31. Ahmad S., et al., Subtractive Genomics, Molecular Docking and Molecular Dynamics Simulation Revealed LpxC as a Potential Drug Target Against Multi-Drug Resistant Klebsiella pneumoniae. Interdiscip Sci, 2019. 11(3): p. 508–526. https://doi.org/10.1007/s12539-018-0299-y PMID: 29721784

32. Kaur H., Kalia M., and Taneja N., Identification of novel non-homologous drug targets against *Acinetobacter baumannii* using subtractive genomics and comparative metabolic pathway analysis. Microb Pathog, 2021. 152: p. 104608. https://doi.org/10.1016/j.micpath.2020.104608 PMID: 32166618

33. Rodriguez R.L., et al., Iterative subtractive binning of freshwater chronosequences metagenomes identifies over 400 novel species and their ecologic preferences. Environ Microbiol, 2020. 22(8): p. 3394–3412. https://doi.org/10.1111/1462-2920.15112 PMID: 32495495
34. Chandela R., et al., Identification of Therapeutic drug Target of *Stenotrophomonas maltophilia* through subtractive genomic approach and in-silico screening based on 2D similarity filtration and Molecular Dynamic Simulation. Comb Chem High Throughput Screen, 2020. https://doi.org/10.2174/187152062066201123094330 PMID: 33231154

35. Shahid F., et al., In Silico Subtractive Proteomics Approach for Identification of Potential Drug Targets in *Staphylococcus saprophyticus*. Int J Environ Res Public Health, 2020. 17(10). https://doi.org/10.3390/ijerph17103644 PMID: 32455889

36. Abuthakir M.H.S., et al., Putative Drug Target Identification in Tinea Causing Pathogen Trichophyton rubrum Using Subtractive Proteomics Approach. Curr Microbiol, 2020. 77(10): p. 2953–2962. https://doi.org/10.1007/s00284-020-02114-z PMID: 32681311

37. Studer G., et al., QMEANDisCo-distance constraints applied on model quality estimation. Bioinformatics, 2020. 36(6): p. 1765–1771. https://doi.org/10.1093/bioinformatics/btz828 PMID: 31697312

38. Koutsouleris N., et al., Multimodal Machine Learning Workflows for Prediction of Psychosis in Patients With Clinical High-Risk Syndromes and Recent-Onset Depression. JAMA Psychiatry, 2021. 78(2): p. 195–209. https://doi.org/10.1001/jamapsychiatry.2020.3604 PMID: 33263726

39. Kryshtafovych A., et al., Critical assessment of methods of protein structure prediction (CASP)-Round XIII. Proteins, 2019. 87(12): p. 1011–1020. https://doi.org/10.1002/prot.25823 PMID: 31589781

40. Pinzi L. and Rastelli G., Molecular Docking: Shifting Paradigms in Drug Discovery. Int J Mol Sci, 2019. 20(18). https://doi.org/10.3390/ijms20184331 PMID: 31487867

41. Desale V.J., et al., Synthesis, admetSAR predictions, DPPH radical scavenging activity and potent antimycobacterial studies of hydrazones of substituted 4-(anilinomethyl)benzohydrazides (Part 2). Curr Comput Aided Drug Des, 2020.

42. Adki K.M., Murugesan S., and Kulkarni Y.A., In Silico and In Vivo Toxicological Evaluation of Paeonol. Chem Biodivers, 2020. 17(10): p. e2000422. https://doi.org/10.1002/cbdv.202000422 PMID: 32955165

43. García-Jacas C.R., et al., Enhancing Acute Oral Toxicity Predictions by using Consensus Modeling and Algebraic Form-Based 0D-to-2D Molecular Encodes. Chem Res Toxicol, 2019. 32(6): p. 1178–1192. https://doi.org/10.1021/acs.chemrestox.9b00011 PMID: 31066547

44. Samonis G, Karageorgopoulos DE, Maraki S, Levis P, Dimopoulou D, Spernovasilis NA, et al. Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome. PloS one. 2012 May 18; 7(5):e37375. https://doi.org/10.1371/journal.pone.0037375 PMID: 22624022